Prof. Erwin DREESEN, PharmD PhD
Assistant professor and head of the Pharmacometrics Research Group in the Department of Pharmaceutical and Pharmacological Sciences, KU Leuven

Model-Informed Precision Dosing: From Theory to Practice

Related publications:
•    Hoffert Y, Wang Z, Fumery M, Nachury M, Bazoge M, Buisson A, Dreesen E. A Risk Stratification Tool for Relapse After Intravenous-To-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases. Am J Gastroenterol. 2026 Jan 1;121(1):179-186. doi: 10.14309/ajg.0000000000003466.
•    Vuong ML, Elkayal O, Van Daele R, Alffenaar JC, Stocker SL, Roberts JA, Debaveye Y, Wauters J, Mertens B, Boonstra JM, Sandaradura I, Marriott DJE, Brüggemann RJ, Schouten JA, Bergner R, Buijk S, Spriet I, Dreesen E. A fluconazole population pharmacokinetics study to improve target attainment in critically ill patients. Infection. 2025 Oct 14. doi: 10.1007/s15010-025-02663-0. 
•    Kantasiripitak W, Outtier A, Wicha SG, Kensert A, Wang Z, Sabino J, Vermeire S, Thomas D, Ferrante M, Dreesen E. Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases. CPT Pharmacometrics Syst Pharmacol. 2022;11(8):1045-1059. doi: 10.1002/psp4.12813.

Info: laure.elens@uclouvain.be